Work

Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature

Year: 2025

Type: article

Abstract: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has demonstrated significant clinical activity and tolerability in EGFR-positive non-small cell lung cancer (NSCLC) patients. However, acquired resistance to osimertinib is inevitable, and the mechanisms underlying resistance to third-generation EGFR-TKIs remain complex and not fully understood. In this case, we report a patient with EGFR-mutated NSCLC who progressed on first-line osimertinib treatment, acquiring a nuclear receptor coactivator 4-rearranged during transfection (NCOA4-RET) fusion alongside a co-mutation in the tumor protein p53 (TP53) gene. Despite these genomic alterations, the patient derived notable clinical benefit from the combination of osimertinib and selpercatinib, suggesting that this dual therapy may offer a promising approach to overcoming resistance in such cases.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2025.1580322

Authors: Blerina Resuli, Heidi Galarza, Diego Kauffmann-Guerrero, Julian Oversohl, Jürgen Behr, Amanda Tufman

Institutions: LMU Klinikum, German Center for Lung Research, Ludwig-Maximilians-Universität München

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801